Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that are designed to analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient’s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its own sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.
Myriad Genetics Inc Key Recent Developments
Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
Oct 21, 2016: Myriad Genetics Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation’s Largest Network of Community Oncologists
Oct 17, 2016: Myriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting
Oct 04, 2016: The US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing
Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Myriad Genetics Inc - Key Facts 6
Myriad Genetics Inc - Key Employees 7
Myriad Genetics Inc - Key Employee Biographies 8
Myriad Genetics Inc - Major Products and Services 9
Myriad Genetics Inc - History 10
Myriad Genetics Inc - Company Statement 18
Myriad Genetics Inc - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Section 2 – Company Analysis 21
Myriad Genetics Inc - Business Description 21
Myriad Genetics Inc - Corporate Strategy 22
Myriad Genetics Inc - SWOT Analysis 23
SWOT Analysis - Overview 23
Myriad Genetics Inc - Strengths 23
Myriad Genetics Inc - Weaknesses 24
Myriad Genetics Inc - Opportunities 25
Myriad Genetics Inc - Threats 26
Myriad Genetics Inc - Key Competitors 27
Section 3 – Company Financial Ratios 28
Financial Ratios - Capital Market Ratios 28
Financial Ratios - Annual Ratios 29
Performance Chart 31
Financial Performance 31
Financial Ratios - Interim Ratios 32
Financial Ratios - Ratio Charts 33
Section 4 – Company’s Lifesciences Financial Deals and Alliances 34
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 34
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 35
Myriad Genetics Inc, Recent Deals Summary 36
Section 5 – Company’s Recent Developments 37
Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results 37
Oct 21, 2016: Myriad Genetics Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation’s Largest Network of Community Oncologists 39
Oct 17, 2016: Myriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting 40
Oct 04, 2016: The US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing 41
Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy 42
Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results 43
May 19, 2016: Myriad Genetics' Statement on HIPAA Complaint from Four Patients 45
May 18, 2016: Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information 46
May 03, 2016: Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results 47
Mar 21, 2016: Myriad Genetics Teams Up with Access Health to Educate the Public about Hereditary Cancer and Genetic Testing 49
Section 6 – Appendix 50
Methodology 50
Ratio Definitions 50
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Tables
Myriad Genetics Inc, Key Facts 6
Myriad Genetics Inc, Key Employees 7
Myriad Genetics Inc, Key Employee Biographies 8
Myriad Genetics Inc, Major Products and Services 9
Myriad Genetics Inc, History 10
Myriad Genetics Inc, Subsidiaries 19
Myriad Genetics Inc, Key Competitors 27
Myriad Genetics Inc, Ratios based on current share price 28
Myriad Genetics Inc, Annual Ratios 29
Myriad Genetics Inc (Cont...1), Annual Ratios 30
Myriad Genetics Inc, Interim Ratios 32
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 34
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 35
Myriad Genetics Inc, Recent Deals Summary 36
Currency Codes 50
Capital Market Ratios 50
Equity Ratios 51
Profitability Ratios 51
Cost Ratios 52
Liquidity Ratios 52
Leverage Ratios 52
Efficiency Ratios 53
List of Figures
Myriad Genetics Inc, Performance Chart (2012 - 2016) 31
Myriad Genetics Inc, Ratio Charts 33
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 34
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 35